The advantages from the IHC-based approaches: the ready availability; its inexpensive nature; rapid turnaround time; rapid identification of the defective protein; correlation with morphology; the need of only a limited amount of tissue; feasibility for all types of FFPE specimens (small biopsies and/or surgical samples); the propensity to IHC external quality assurance schemes

The advantages from the IHC-based approaches: the ready availability; its inexpensive nature; rapid turnaround time; rapid identification of the defective protein; correlation with morphology; the need of only a limited amount of tissue; feasibility for all types of FFPE specimens (small biopsies and/or surgical samples); the propensity to IHC external quality assurance schemes. The majority of Italian labs (47.5%) perform MMR IHC in all EC samples, while 32.5% perform it only in presence of morphological/clinical suspicion of Lynch Syndrome and in early-stage cancers. MMR protein expression immunohistochemical screening offers advantages and difficulties in identifying MMRd cases that potentially could benefit from immunotherapy and/or radiation therapy and in determined patients with Lynch Syndrome (LS), who should therefore be referred for genetic counseling and surveillance programs. microsatellite instability (MSI), were collected. A summary and a descriptive statistical analysis were used to show the current practice of each laboratory. Results The analysis of MMR status by immunohistochemistry (IHC) is usually carried out on the majority of all EC samples. The most frequent strategy for the analysis of MMR status in EC is usually IHC of four proteins (PMS2, MSH6, MSH2, MLH1). MSI analysis by molecular method in endometrial malignancy is usually rarer and more restricted to some circumstances. Hypermethylation of the promoter by methylation-specific PCR and pyrosequencing was analyzed in case of unfavorable expression of MLH1/PMS2. Also, the analysis of p53 in EC is performed in the majority of cases. mutational profiling is usually adopted only in a limited quantity of laboratories. Fifty-five percent of Italian laboratories refer to national/international guidelines when analyzing biomarkers in EC (among those, 45% use the ESGO Guidelines, 18% ASCO-CAP, 18% AIOM, 14% WHO, 5% British Association of Gynaecological Pathologist, 5% ESMO, 5% NCCN). Conclusions Adoption of guidelines and standardization of pre-analytical and analytical procedures are effective tools for adequate EC prognostic risk stratification and high quality standard of care. promoter hypermethylation (28%), and p.V600E evaluation IL9R (6%) or p.V600/ MSI + p.V600 Pyrosequencing/ RT-PCR/ Genetic counseling. MLH1 PROMOTER METHYLATION ANALYSIS: METHODS How do you perform it? The most frequent methods for the analysis of promoter hypermethylation are methylation-specific PCR and pyrosequencing, respectively used in 38% and 31% of cases (Fig. 4A). Open in a separate window Physique 4. (A) MLH1 promoter hypermethylation in EC: which technology? (B) Other biomarkers in endometrial carcinoma. OTHER BIOMARKERS Do you also routinely analyze p53 antibody in EC? In EC molecular characterization, numerous other prognostic and diagnostic molecules are employed. P53, together with MMR proteins, represents the most analyzed, with 85% of Italian Labs analyzing it by IHC: an interesting data, when compared to other molecules, such as ER and PR, analyzed only by 10% of Italian labs. A large number of laboratories analyzed more than one biomarker (Fig. 4B). FOCUS ON POLE MUTATIONAL ANALYSIS Do you perform POLE mutational analysis? If yes in which cases? Only 3 Italian labs (8%) perform mutational analysis, by a panel testing focused on the exonuclease domain name of exons 9, 11, 13, 14, in order to detect the pathogenetic mutations variants (P286AR, V411L, S297F, A456P, S459F, F367S, L424I, M295R, P436R, M444K, D368Y). In 1 of these 3 labs the molecular analysis was restricted to particularly circumstances, on request by the clinicians, especially in high grade, rare, ambiguous, and mixed histologies, in presence of large quantity in TIL and/or peritumoral lymphocytes, in cases with ambiguous immunophenotype (possible multiple classifiers) or with subclonal p53 at IHC. In the other 2 labs, molecular analysis is performed in all Difloxacin HCl cases. In 37 laboratories (90%), there was no availability of molecular evaluation. GUIDELINES Which national/international guidelines do you refer to classify prognostic risk in endometrial malignancy? Difloxacin HCl 55% of Italian laboratories referred to national/international guidelines, analyzing biomarkers in EC (Fig. 5): 45% of labs refer to ESGO guidelines, 18% ASCO-CAP and 14% WHO. British association of gynecological pathologist guidelines, ESMO and NCCN were adopted in a lower percentage of cases. Open in a separate window Physique 5. International/national guidelines in EC. Conversation SUMMARY OF MAIN RESULTS The present study represents the first survey analysis resolved to 41 Italian labs, focusing on the most commonly adopted immunohistochemical and molecular biomarkers in daily clinical characterization of a diagnosed EC. The first emerging data regards the IHC that still turns out as the standard ancillary tool in diagnostic pathology. The advantages of the IHC-based methods: the ready availability; its inexpensive nature; rapid turnaround time; rapid identification of the defective protein; correlation with morphology; the need of only a limited amount of tissue; feasibility for all types of FFPE specimens (small biopsies and/or surgical samples); the propensity to IHC external quality assurance techniques. The majority of Italian labs (47.5%) perform MMR IHC in all EC samples, while 32.5% perform it only in presence of morphological/clinical suspicion of Lynch Syndrome and in early-stage Difloxacin HCl cancers. MMR protein expression immunohistochemical screening offers advantages and difficulties in identifying MMRd cases that potentially could benefit from immunotherapy and/or radiation therapy and in selected patients with Lynch Syndrome (LS), who should therefore be referred for genetic counseling and surveillance programs. 97% of Italian laboratories screening MMR use an immunoistochemical panel. Although a combination of only two antibodies MSH6 and PMS2 might reduce the cost without significantly decreasing the diagnostic accuracy, the immunohistochemical evaluation of 4 MMR proteins is confirmed as first choice test, followed by MSI analysis. The two methods have comparable sensitivity and show.